Arcutis officer Matsuda proposes $38.8K share sale

The 1,219 shares identified for sale are listed as acquired through restricted stock vesting on November 1, 2026.

Available on EDGAR 11/02/2026 - 05:28 PM EST Accepted by SEC EDGAR 11/02/2026 - 05:27 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. officer Masaru Matsuda reported a proposed sale of 1,219 common shares, with an aggregate market value of $38,841.48, through Merrill Lynch. The notice lists an approximate sale date of November 2, 2026, on Nasdaq. It also lists earlier sales of 9,989 shares for $249,986.12 on September 8, 2026, and 3,674 shares for $91,853.24 on September 16, 2026.

Key Figures

Proposed shares for sale: 1,219 shares Aggregate market value: $38,841.48 Shares outstanding: 125,691,961 shares +4 more

7 metrics

Proposed shares for sale 1,219 shares Common shares; approximate sale date November 2, 2026

Aggregate market value $38,841.48 Proposed sale

Shares outstanding 125,691,961 shares Issuer shares outstanding

Earlier shares sold 9,989 shares September 8, 2026

Earlier sale value $249,986.12 September 8, 2026

Earlier shares sold 3,674 shares September 16, 2026

Earlier sale value $91,853.24 September 16, 2026

Key Terms

Rule 144, Restricted Stock Vesting, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

aggregate market value financial

"Aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARQT shares is Masaru Matsuda planning to sell?

The notice lists a proposed sale of 1,219 common shares with an aggregate market value of $38,841.48 through Merrill Lynch, with an approximate sale date of November 2, 2026.

How did Masaru Matsuda acquire the ARQT shares listed for sale?

The notice lists the 1,219 common shares as acquired through restricted stock vesting on November 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001798679
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Masaru Matsuda
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	1219	38841.48	125691961	11/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			1219	11/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Masaru Matsuda 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	09/08/2026	9989	249986.12
Masaru Matsuda 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	09/16/2026	3674	91853.24

144: Remarks and Signature

Remarks
Date of Notice	11/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Masaru Matsuda
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)